A Combination Study of Rucaparib and Atezolizumab in Participants With Advanced Gynecologic Cancers and Triple-Negative Breast Cancer

NCT03101280 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

29

Enrollment

INDUSTRY

Sponsor class

Conditions

Gynecologic Neoplasms

Interventions

DRUG: Atezolizumab
DRUG: Rucaparib

Sponsor

Hoffmann-La Roche